EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseSystematische Übersicht

Efficacy and safety of CGRP monoclonal antibodies for migraine prevention in episodic migraine; a network Meta-analysis

Ishwa Shakir, Faizan Shahzad, Ahsan Shabbir, Saba Shahabuddin, Haroon Shabbir, Sobia Karamat, Saad Hulou, Abdul Rauf Khalid, Syed Ijlal Ahmed

European Journal of Clinical Pharmacology · 2026

DOI: 10.1007/s00228-025-03934-3 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift European Journal of Clinical Pharmacology, 2026. Verfasst von Ishwa Shakir und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, Islamic International Medical College, Rawalpindi, Pakistan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Calcitonin Gene-Related Peptide, Migraine Disorders. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND PURPOSE: Episodic migraine is a neurological disorder characterized by recurrent, unilateral headaches that significantly impair quality of life. CGRP monoclonal antibodies, targeting calcitonin gene-related peptide (CGRP), have shown efficacy in preventing and treating episodic migraine. METHODS: A systematic search of PubMed, Cochrane, and Embase databases was conducted in September 2024 to identify randomized controlled trials (RCTs) on CGRP monoclonal antibodies for episodic migraine. A network meta-analysis was performed to assess efficacy (change in monthly migraine days) and safety (incidence of adverse events). Odds ratios (ORs) and surface under the cumulative ranking curve (SUCRA) were calculated. RESULTS: 16 studies with 9,123 participants were included. galcanezumab (240 mg) showed the highest efficacy (SMD = 0.5012, p < 0.0001). fremanezumab (225 mg) had the highest odds of ≥ 50% reduction in migraine days (OR = 3.1684, p < 0.0001). erenumab (28 mg) showed the best safety profile (OR = 0.6815, p = 0.2220). fremanezumab ranked highest in both efficacy (SUCRA = 84.6%) and safety (SUCRA = 61.8%). CONCLUSION: fremanezumab offers the best balance of efficacy and safety. Further long-term studies are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalCalcitonin Gene-Related PeptideMigraine DisordersHumansAntibodies, Monoclonal, HumanizedNetwork Meta-Analysis as TopicRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

CGRP monoclonal antibodiesGalcanezumabMigraine preventionSafety and efficacyErenumabFremanezumabMigraineNetwork meta-analysis

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptideerenumabfremanezumabgalcanezumab

Autor:innen und Institutionen

  • College of Medicine, Islamic International Medical College, Rawalpindi, Pakistan.
  • College of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
  • College of Medicine, United Medical and Dental College, Karachi, Pakistan.
  • College of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan.
  • Department of Ophthalmology, Amir Eye Hospital, Rawalpindi, Pakistan.
  • College of Medicine, University of Aleppo, Aleppo, Syria. Saad.Hulou98@gmail.com.

Zitieren

APA

Shakir, I., Shahzad, F., Shabbir, A., Shahabuddin, S., Shabbir, H., Karamat, S., Hulou, S., Khalid, A. R., & Ahmed, S. I. (2026). Efficacy and safety of CGRP monoclonal antibodies for migraine prevention in episodic migraine; a network Meta-analysis. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-025-03934-3

Vancouver

Shakir I, Shahzad F, Shabbir A, Shahabuddin S, Shabbir H, Karamat S, et al. Efficacy and safety of CGRP monoclonal antibodies for migraine prevention in episodic migraine; a network Meta-analysis. European Journal of Clinical Pharmacology. 2026. doi:10.1007/s00228-025-03934-3

BibTeX
@article{Shakir2026,
  author = {Shakir, Ishwa and Shahzad, Faizan and Shabbir, Ahsan and Shahabuddin, Saba and Shabbir, Haroon and Karamat, Sobia and Hulou, Saad and Khalid, Abdul Rauf and Ahmed, Syed Ijlal},
  title = {Efficacy and safety of CGRP monoclonal antibodies for migraine prevention in episodic migraine; a network Meta-analysis},
  journal = {European Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1007/s00228-025-03934-3}
}
Kostenlos starten →